Investors Press Releases Mar 31 2023 Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in Swe Read More Mar 28 2023 Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) Read More Mar 17 2023 Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO Read More btn News View All Events & Presentations Jan 09 2023 - Jan 11 2023 Jan 09 2023 - Jan 11 2023 Biotech Showcase Read More Dec 29 2022 Dec 29 2022 Annual General Meeting 2022 Read More Nov 10 2022 at 10:00 AM EST Nov 10 2022 at 10:00 AM EST Investor call Read More btn Events View All Interim Reports Interim Results for the Six Months Ended 30 June 2022 641.6 KB bth Interim Reports View All Annual Reports 20 F - Annual Report for the year ended 31 December 2021 1.9 MB btn ARs View All Annual General Meeting Notice of Annual General Meeting December 2022 276.9 KB btn AGM View All Scientific Pipeline Progress Learn more × Stock Quote Change Volume Today's Open Previous Close Today's High Today's Low 52 Week High 52 Week Low Stock Chart
Mar 31 2023 Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in Swe Read More
Mar 28 2023 Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) Read More
Mar 17 2023 Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO Read More